Overview ALPN-101 in Systemic Lupus Erythematosus Status: Recruiting Trial end date: 2024-01-01 Target enrollment: Participant gender: Summary This is Phase 2, multinational, randomized, blinded study to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics and pharmacodynamics of ALPN-101 in adults with moderate to severe active systemic lupus erythematosus (SLE) Phase: Phase 2 Details Lead Sponsor: Alpine Immune Sciences, Inc.